Publications by authors named "Alan MacInnes"

Claim this Profile
I
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.
Robert O Hughes, Todd Maddux, D Joseph Rogier, Sharon Lu, John K Walker, Alan Macinnes

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.
Craig L Hyde, Alan Macinnes, Frances A Sanders, John F Thompson, Richard A Mazzarella

Circ Cardiovasc Genet· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, John K Walker, Alan Macinnes

J Med Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.
Robert O Hughes, John K Walker, D Joseph Rogier, Steve E Heasley, Rhadika M Blevis-Bal, Alan MacInnes

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system.
Robert O Hughes, John K Walker, Jerry W Cubbage, Yvette M Fobian, D Joseph Rogier, Alan Macinnes

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Dafydd R Owen, John K Walker, E Jon Jacobsen, John N Freskos, Robert O Hughes, Alan Macinnes

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
David J Baker, Paul L Greenhaff, Alan MacInnes, James A Timmons

Diabetes· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic adaptations to repeated periods of contraction with reduced blood flow in canine skeletal muscle.
Alan MacInnes, James A Timmons

BMC Physiol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Alan MacInnes, David A Fairman, Peter Binding, Jo ann Rhodes, Michael J Wyatt

Circ Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis